FDA Advisory Committee Votes Favoring Restricted Use Of AstraZeneca/Merck's Prostate Cancer Drug

  • The FDA's Oncologic Drugs Advisory Committee (ODAC) voted against AstraZeneca Plc AZN and Merck & Co Inc's MRK application seeking approval for expanded use of Lynparza (olaparib) to all adult patients with metastatic castration-resistant prostate cancer (mCRPC).
  • With one abstaining, the Committee voted 11 to 1 that the indication should be limited to patients whose tumors have a BRCA mutation.
  • The companies sought approval for Lynparza plus abiraterone and prednisone or prednisolone for BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC).
  • The FDA has already approved Lynparza to treat a type of breast cancer, ovarian cancer, and a different form of prostate cancer.
  • In August, the FDA granted the drug priority review. However, AstraZeneca and Merck revealed a delay for the FDA review in December.
  • Just two days before the adcomm, the FDA released a briefing document and raised concerns about the safety and efficacy data.
  • In the document, the agency pointed to a subgroup of patients without a BRCA mutation, saying that the data the companies have submitted may not be sufficient to expand use in that group.
  • Lynparza achieved a radiographic progression-free survival of 24.8 months, compared to 16.6 months in the control group, and a 34% reduction in the risk of disease progression or death compared to the control.
  • Price Action: AZN shares closed at $73.22, and MRK shares closed at $115.47 on Friday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechLarge CapNewsHealth CareFDAGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!